Hallenberger Tim Jonas, Fischer Urs, Ghosh Nilabh, Kuhle Jens, Guzman Raphael, Bonati Leo Hermann, Soleman Jehuda
Department of Neurosurgery, University Hospital Basel, Basel, Switzerland.
Faculty of Medicine, University of Basel, Basel, Switzerland.
Front Neurol. 2024 Nov 19;15:1484255. doi: 10.3389/fneur.2024.1484255. eCollection 2024.
Whether minimally invasive endoscopic surgery (ES) improves survival and functional outcome in people with spontaneous supratentorial intracerebral hemorrhage (SSICH) is unknown.
This is a single-center pilot study performed between July 2021 to January 2023. Any supratentorial hematoma with a volume between 20 mL and 100 mL was endoscopically evacuated within 24 h after bleeding onset. Participants were followed-up for 6 months, assessing clinical and radiological outcomes. The primary feasibility outcome was satisfactory hematoma removal (<15 mL residual volume on the first postinterventional CT study) and the primary efficacy outcome was reaching a modified Rankin Scale 0-3 (mRS) at 6 months. Secondary outcomes were mortality and morbidity rates.
Ten participants (median age 72.5 years [IQR 67-81], 70% male, median baseline hematoma volume 34.1 [IQR 25.5-58.0]) were included. Satisfactory hematoma evacuation was achieved in 70% (7/10) with a median evacuation percentage of 69.5% [IQR 45.3-93.9%]. The median duration of surgery was 91 min [IQR 73-111]. Favorable outcome at 6 months was observed in 60% of the participants and improved from within 24 h before the intervention to the last follow-up (6 months). Five participants (50%) experienced a total of six complications, two recurrent bleedings, three pneumonias and one epilepsy. Mortality rate was 30%, while one participant died from pneumonia, one from a recurrent bleeding, and one participant due to a glioblastoma.
ES appears to be feasible, with satisfactory hematoma removal being achieved in the majority of participants. Based on the descriptive results of this pilot trial, a national multicenter RCT comparing ES to best medical treatment is currently ongoing.
https://clinicaltrials.gov/, identifier NCT05681988.
微创内镜手术(ES)是否能改善自发性幕上脑出血(SSICH)患者的生存率和功能预后尚不清楚。
这是一项于2021年7月至2023年1月进行的单中心试点研究。任何幕上血肿体积在20毫升至100毫升之间的患者在出血发作后24小时内接受内镜下血肿清除术。对参与者进行6个月的随访,评估临床和影像学结果。主要可行性结果是血肿清除满意(介入后首次CT检查时残余体积<15毫升),主要疗效结果是6个月时达到改良Rankin量表0-3级(mRS)。次要结果是死亡率和发病率。
纳入了10名参与者(中位年龄72.5岁[四分位间距67-81],70%为男性,中位基线血肿体积34.1[四分位间距25.5-58.0])。70%(7/10)的患者实现了满意的血肿清除,中位清除率为69.5%[四分位间距45.3-93.9%]。中位手术时间为91分钟[四分位间距73-111]。60%的参与者在6个月时观察到良好结局,且从干预前24小时内到最后一次随访(6个月)有所改善。5名参与者(50%)共经历了6次并发症,2次再出血,3次肺炎和1次癫痫发作。死亡率为30%,其中1名参与者死于肺炎,1名死于再出血,1名死于胶质母细胞瘤。
ES似乎是可行的,大多数参与者实现了满意的血肿清除。基于该试点试验的描述性结果,一项比较ES与最佳药物治疗的全国多中心随机对照试验正在进行中。